Analysts Set Vor Biopharma Inc. (NYSE:VOR) Target Price at $11.36

Vor Biopharma Inc. (NYSE:VOR) has received a consensus recommendation of “Buy” from the seven ratings firms that are presently covering the stock, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $11.36.

Several analysts have issued reports on VOR shares. JMP Securities reissued a “market outperform” rating and issued a $12.00 price target on shares of Vor Biopharma in a research note on Tuesday, December 10th. HC Wainwright reaffirmed a “buy” rating and issued a $17.50 target price on shares of Vor Biopharma in a research report on Tuesday, December 10th. Robert W. Baird lowered their target price on Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $11.00 target price on shares of Vor Biopharma in a research report on Monday, December 9th.

Hedge Funds Weigh In On Vor Biopharma

Institutional investors have recently bought and sold shares of the business. Acadian Asset Management LLC boosted its stake in shares of Vor Biopharma by 51.4% in the second quarter. Acadian Asset Management LLC now owns 81,305 shares of the company’s stock valued at $79,000 after buying an additional 27,597 shares during the period. Hsbc Holdings PLC raised its position in Vor Biopharma by 177.0% during the second quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock valued at $51,000 after purchasing an additional 31,333 shares in the last quarter. Exchange Traded Concepts LLC raised its position in Vor Biopharma by 40.8% during the third quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company’s stock valued at $116,000 after purchasing an additional 48,017 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in Vor Biopharma during the second quarter valued at approximately $53,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Vor Biopharma during the second quarter valued at approximately $63,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Price Performance

VOR opened at $1.37 on Friday. The business’s 50-day moving average price is $1.00 and its two-hundred day moving average price is $0.91. Vor Biopharma has a 1 year low of $0.63 and a 1 year high of $2.59. The company has a market capitalization of $94.08 million, a price-to-earnings ratio of -0.83 and a beta of -0.51.

Vor Biopharma (NYSE:VOR) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.40). Sell-side analysts anticipate that Vor Biopharma will post -1.55 earnings per share for the current fiscal year.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.